AXL and breast carcinoma: Even though one of AXL interacting proteins, ELMO2, was found to be upregulated upon the exposure of CB agonists, the significantly decreased AXL, VAV2 and RAC1 as well as the diminished cell migration and invasion seen in previous and current studies indicated that negative effects of CB agonists on breast cancer cell motility might occur in ELMO2 independent pathway [10, 83].